SequelSEC

ONCOLYTICS BIOTECH INC ONCY

Pharmaceutical Preparations · CIK 0001129928 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2026-06-30
Operating income
-$9.38M
Fiscal year ended 2026-06-30
Free cash flow
-$8.14M
Fiscal year ended 2026-06-30

ONCOLYTICS BIOTECH INC (ONCY) reported net income of -$9.44M for the fiscal year ended 2026-06-30. This page shows 6 annual periods of income statement, balance sheet and cash flow figures normalized from ONCOLYTICS BIOTECH INC’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

ONCOLYTICS BIOTECH INC income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-06-302025-03-312024-12-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$9.38M-$9.28M-$19.05M-$4.65M-$5.02MUnavailable
Net income-$9.44M-$9.24M-$18.77M-$5.28M-$4.71MUnavailable
Research & development$4.26M$4.55M$8.60M$1.92M$2.80MUnavailable
Weighted-average diluted sharesshares 119.74Mshares 112.29MUnavailableshares 91.00Mshares 84.63MUnavailable
Pretax income-$9.34MUnavailable-$18.75M-$5.22MUnavailableUnavailable
Income tax expense$101.00KUnavailable$18.00K$61.00KUnavailableUnavailable
Diluted EPS$-0.08$-0.08Unavailable$-0.06$-0.06Unavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$5.12M$4.73M$10.46M$2.74M$2.22MUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

ONCOLYTICS BIOTECH INC balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-06-302025-03-312024-12-31
Cash & equivalents$4.12M$5.49M$5.20MUnavailableUnavailable$11.08M
Total assets$7.67M$8.16M$7.58MUnavailableUnavailable$13.42M
Current assets$7.07M$7.49M$6.84MUnavailableUnavailable$12.44M
Total liabilities$13.84M$13.29M$11.38MUnavailableUnavailable$10.12M
Current liabilities$5.22M$5.42M$6.10MUnavailableUnavailable$4.88M
Total equity incl. NCI-$6.17M-$5.13M-$3.80M$3.70M$3.72M$3.30M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$3.40M$2.68M$3.50MUnavailableUnavailable$756.00K

Cash flow

ONCOLYTICS BIOTECH INC cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-06-302025-03-312024-12-31
Operating cash flow-$8.14M-$7.29M-$11.27M-$4.11M-$4.73MUnavailable
Capital expenditures$0$6.00K$5.00K$0$1.00KUnavailable
Investing cash flow$0-$6.00K-$5.00K$0-$1.00KUnavailable
Financing cash flow$6.77M$7.61M$5.84M$4.09M$4.18MUnavailable
Net change in cash-$1.38M$291.00K-$5.52M$76.00K-$434.00KUnavailable
Stock-based compensation$1.79M$2.30M$1.90M$362.00K$845.00KUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

ONCOLYTICS BIOTECH INC derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-06-302025-03-312024-12-31
Free cash flow-$8.14M-$7.30M-$11.28M-$4.11M-$4.73MUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio1.35x1.38x1.12xUnavailableUnavailable2.55x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ONCY in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-12View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-K · Filed 2026-03-30View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.